Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells

Deubiquitinases (DUBs) play important roles in various human cancers and targeting DUBs is considered as a novel Anticancer therapeutic strategy. Overexpression of ubiquitin specific Protease 7 and 22 (USP7 and USP22) are associated with malignancy, therapy resistance, and poor prognosis in many cancers. Although both DUBs are involved in the regulation of similar genes and signaling pathways, such as histone H2B monoubiquitination (H2Bub1), c-Myc, FOXP3, and p53, the interdependence of USP22 and USP7 expression has never been described. In the study, we found that targeting USP7 via either siRNA-mediated knockdown or pharmaceutical inhibitors dramatically upregulates USP22 in Cancer cells. Mechanistically, the elevated USP22 occurs through a transcriptional pathway, possibly due to desuppression of the transcriptional activity of SP1 via promoting its degradation upon USP7 inhibition. Importantly, increased USP22 expression leads to significant activation of downstream signal pathways including H2Bub1 and c-Myc, which may potentially enhance Cancer malignancy and counteract the Anticancer efficacy of USP7 inhibition. Importantly, targeting USP7 further suppresses the in vitro proliferation of USP22-knockout (USP22-Ko) A549 and H1299 lung Cancer cells and induces a stronger activation of p53 tumor suppressor signaling pathway. In addition, USP22-Ko Cancer cells are more sensitive to a combination of cisplatin and USP7 Inhibitor. USP7 Inhibitor treatment further suppresses in vivo angiogenesis and tumor growth and induced more Apoptosis in USP22-Ko Cancer xenografts. Taken together, our findings demonstrate that USP7 inhibition can dramatically upregulate USP22 in Cancer cells; and targeting USP7 and USP22 may represent a more effective approach for targeted Cancer therapy, which warrants further study. Video Abstract.

Deubiquitinase; SP1; Targeted anticancer therapy; USP22; USP7; c-Myc; p53.